What one share of Cardiff Oncology holds
We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care ("SoC") therapeutics.
Cardiff Oncology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.59 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.60 |
| Cash and investments | $0.13 |
| Book value | $0.37 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $1.05 | −$51.76 | $0.21 | −$48.54 | — | $8.87 |
| 2018 | $0.16 | −$8.26 | $0.00 | −$5.67 | — | $2.63 |
| 2019 | $0.04 | −$2.80 | $0.01 | −$2.23 | — | $0.85 |
| 2020 | $0.02 | −$1.08 | $0.01 | −$0.79 | — | $3.48 |
| 2021 | $0.01 | −$0.73 | $0.01 | −$0.60 | — | $3.35 |
| 2022 | $0.01 | −$0.89 | $0.02 | −$0.80 | — | $2.36 |
| 2023 | $0.01 | −$0.93 | $0.01 | −$0.70 | — | $1.54 |
| 2024 | $0.01 | −$0.95 | $0.00 | −$0.79 | — | $1.23 |
| 2025 | $0.01 | −$0.69 | $0.00 | −$0.57 | — | $0.65 |
Common questions about Cardiff Oncology
How much does one share of Cardiff Oncology earn?
Over the last 12 months, Cardiff Oncology lost $0.59 for each share on $0.01 of sales.
Does Cardiff Oncology pay a dividend?
Cardiff Oncology didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Cardiff Oncology’s book value per share?
Cardiff Oncology’s book value is $0.37 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Cardiff Oncology have?
Each share of Cardiff Oncology has $0.13 of cash and investments, as of June 30, 2026.
What is Cardiff Oncology’s free cash flow per share?
−$0.60 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Cardiff Oncology bought back shares?
Cardiff Oncology’s share count rose about 13777% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.